Abcellera Biologics Inc

Healthcare · Biotechnology

12.80$ -2.4% vs. previous close Closing price · As of: Oct 7, 2026

Statements

Balance Sheet

Abcellera Biologics Inc (ABCL) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Total Assets" came in at 1,308 million USD. Tick rows to compare them in a chart.

Income Statement Balance Sheet Cash Flow Ratios

Annual Quarterly

Amounts Change % Common size %

Last 12 Full history

Download as CSV

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Balance Sheet ABCL
Line item	Q1 19	Q2 19	Q3 19	Q4 19	Q1 20	Q2 20	Q3 20	Q4 20	Q1 21	Q2 21	Q3 21	Q4 21	Q1 22	Q2 22	Q3 22	Q4 22	Q1 23	Q2 23	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26
Total Assets	–	–	–	23	–	155	142	1,006	1,129	1,152	1,173	1,319	1,592	1,594	1,552	1,541	1,498	1,537	1,512	1,488	1,463	1,412	1,393	1,361	1,344	1,402	1,356	1,357	1,307	1,308
Current Assets	10	–	–	13	7.6	129	114	813	908	864	804	930	1,174	1,144	1,046	1,025	941	931	920	872	814	772	743	751	765	742	695	728	665	679
Cash	-10	–	–	7.6	-7.6	113	91	594	686	793	518	476	546	791	372	387	193	180	172	133	124	148	127	156	159	92	83	129	77	120
Cash & Short-Term Investments	10	–	–	7.6	7.6	113	91	594	686	793	753	723	786	1,022	868	886	796	796	786	761	698	670	643	626	605	553	496	534	505	540
Receivables	–	–	–	2.1	15	0.3	5.5	214	23	65	44	161	334	53	106	103	100	86	75	64	69	68	63	92	127	153	159	153	116	95
Inventory	–	–	–	0.2	–	0.0	1.0	1.4	1.2	1.2	1.3	1.7	25	25	25	1.5	1.4	1.4	1.2	1.1	0.7	0.0	–	0.0	–	–	–	6.3	7.9	7.6
Property, Plant & Equipment	–	–	–	8.5	12	12	14	18	35	87	92	112	122	149	201	217	233	260	277	–	–	–	–	–	–	–	–	–	–	–
Goodwill	–	–	–	32	–	32	32	32	32	32	49	48	48	48	48	48	48	48	48	48	48	48	48	48	48	48	48	48	48	48
Intangible Assets	–	–	–	115	–	14	13	115	113	110	149	148	146	143	143	132	129	127	124	120	119	86	53	42	41	40	39	38	37	37
Total Liabilities	–	–	–	13	–	64	53	175	171	184	219	293	385	381	302	308	289	342	329	336	333	302	315	304	321	395	392	390	369	412
Current Liabilities	–	–	–	7.9	18	18	20	103	88	70	50	121	213	221	106	118	90	119	110	119	105	70	80	77	75	67	69	64	47	53
Short-Term Debt	–	–	–	2.9	–	0.8	0.9	0.9	1.5	2.2	2.8	3.7	3.9	4.0	4.5	5.6	5.9	6.0	5.6	6.2	5.5	5.6	5.1	4.6	4.6	4.9	5.2	5.8	5.9	5.7
Accounts Payable	–	–	–	1.6	2.5	2.5	3.0	7.3	3.6	5.6	8.9	15	10	10	9.3	15	18	21	17	29	27	27	35	34	33	32	32	25	21	12
Long-Term Debt	–	–	–	1.4	–	–	1.9	2.2	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Shareholders' Equity	12	–	–	10	10	91	89	831	957	968	953	1,026	1,208	1,213	1,250	1,233	1,209	1,195	1,183	1,152	1,130	1,111	1,078	1,056	1,023	1,007	964	967	938	896
Retained Earnings	–	–	–	-4.7	-0.1	-0.1	-2.8	114	231	229	208	268	436	429	456	426	386	356	327	280	239	202	151	117	71	37	-21	-29	-73	-128
Shares Outstanding	151	151	152	238	238	238	266	320	320	272	279	315	311	285	316	301	288	289	289	291	293	294	295	295	298	299	299	299	303	306

Data as of: October 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?

Balance Sheet

Cookie settings